Tetanus secondary prevention: Difference between revisions
m (Changes made per Mahshid's request) |
m (Bot: Removing from Primary care) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 11: | Line 11: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
[[Category:Bacterial diseases]] | [[Category:Bacterial diseases]] | ||
[[Category:Emergency mdicine]] | |||
[[Category: | [[Category:Up-To-Date]] | ||
[[Category:Infectious disease]] | |||
[[Category:Neurology]] | |||
Latest revision as of 00:25, 30 July 2020
|
Tetanus Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tetanus secondary prevention On the Web |
|
American Roentgen Ray Society Images of Tetanus secondary prevention |
|
Risk calculators and risk factors for Tetanus secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Michael Maddaleni, B.S.
Overview
Tetanus vaccine can prevent tetanus for approximately 10 years. Post-exposure care is indicated in people who do not know exactly when their last tetanus booster was and who did not complete their primary set of vaccinations. These patients will typically receive passive immunity with tetanus immune globulin (TIG).
Secondary Prevention
Currently, there is a large number of people protected by the Tetanus vaccine which can prevent Tetanus for approximately 10 years. The people that would need specific post-exposure care are those who do not know exactly when their last Tetanus booster was. Post-exposure care may also be indicated in people who did not complete their primary prevention set of vaccinations. These patients will typically receive passive immunity with tetanus immune globulin (TIG). In a situation that would involve a large radius of exposure, the TIG will be reserved for the people who are least likely to have had a primary vaccination series. This includes people older than 60 and immigrants from regions other than North America and Europe. The TIG prophylactic dose that is recommended currently for wounds is 250 units administered intramuscularly (IM) for adult and pediatric patients. In circumstances in which passive protection is clearly indicated but TIG is unavailable, intravenous immune globulin may be substituted for TIG.